Related Experiment Video

Updated: Jun 6, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in

Moriko Ito1, Louise Barys, Terence O'Reilly

  • 1Novartis Institutes for Biomedical Research, Oncology Research, Basel, Switzerland. moriko.ito@novartis.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 17, 2010
PubMed
Abstract

Insights

Reactivating p53 tumor suppressor activity is a potential therapy for soft-tissue sarcoma. This study identified TP53 mutations and MDM2 amplification as key biomarkers for sarcoma subtypes and malignancy risk.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor pathway plays a critical role in preventing cancer.
  • Reactivating p53 is a promising therapeutic strategy for various cancers, including soft-tissue sarcoma.
  • Understanding alterations in the p53 pathway is crucial for classifying sarcoma subtypes and identifying therapeutic targets.

Purpose of the Study:

  • To classify sarcoma subtypes based on alterations in the p53 pathway.
  • To define the role of p53 pathway alterations in sarcoma development and malignancy.
  • To identify potential patient biomarkers for targeted therapies in heterogeneous sarcoma diseases.

Main Methods:

  • Systematic analysis of mutational events in 192 bone and soft-tissue sarcomas.
  • Assessment of TP53 and CDKN2A mutational and SNP status.
  • Evaluation of MDM2 and MDM4 amplification and MDM2 SNP309 status.

Main Results:

  • An inverse relationship was observed between MDM2 amplification and TP53 mutations.
  • TP53 point mutations were uniquely prevalent in leiomyosarcoma, osteosarcoma, and MFH.
  • MDM2 and MDM4 coamplification occurred in a subtype-specific manner, and the MDM2 SNP309 G allele associated with liposarcomas and MDM2 amplification.

Conclusions:

  • p53 pathway inactivation is critical in sarcomagenesis, with diverse alterations contributing to disease heterogeneity.
  • TP53 mutation or MDM2 amplification, along with MDM2 SNP309 genotype, are strongly associated with sarcoma malignancy.
  • MDM2 markers and TP53 sequencing are proposed as valuable biomarkers for sarcoma patient stratification in clinical trials involving MDM2 antagonists.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...